Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 1

Status

Completed 19Terminated 5Active not recruiting 5Unknown 3Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5Thoracic 2Head & Neck 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 49Ovarian Neoplasms 44Breast Neoplasms 31Small Cell Lung Carcinoma 25Neoplasms 20Fallopian Tube Neoplasms 16Triple Negative Breast Neoplasms 14Carcinoma, Ovarian Epithelial 14Neoplasm Metastasis 12Adenocarcinoma of Lung 11Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Lymphoma 7Head and Neck Neoplasms 7Carcinoma 7Urinary Bladder Neoplasms 6Esophageal Neoplasms 6Endometrial Neoplasms 6Brain Neoplasms 6Thoracic Neoplasms 5Prostatic Neoplasms 5Melanoma 5Lung Diseases 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Respiratory Tract Neoplasms 4Recurrence 4

Interventions

pembrolizumab 51Ipilimumab 49Cyclophosphamide 43Nivolumab 40aldesleukin 30Interleukin-2 23Vemurafenib 20fludarabine 19Temozolomide 18fludarabine phosphate 15dabrafenib 15trametinib 12Radiosurgery 10Dacarbazine 10CTLA-4 Antigen 10spartalizumab 9cobimetinib 9binimetinib 9Radiotherapy 9poly ICLC 7encorafenib 7Paclitaxel 7atezolizumab 6Introns 6Biopsy 6montanide ISA 51 5Carboplatin 5epacadostat 4MART-1 Antigen 4Interferon alpha-2 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Melanoma × Carboplatin × Clear all
NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Iovance Biotherapeutics, Inc.

Phase 2 Terminated
225 enrolled
DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01009515 2017-10-18

Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

New Mexico Cancer Research Alliance

Phase 2 Terminated
19 enrolled 11 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT01200342 2016-02-11

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

M.D. Anderson Cancer Center

Phase 2 Terminated
7 enrolled 3 charts
Dermatologic

Uveal Melanoma, Melanoma

NCT00568451 2015-12-30

Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma

Mayo Clinic

Phase 2 Terminated
12 enrolled 9 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡